← Leaderboards
Jeffrey Avins Glassberg
Icahn School Of Medicine At Mount Sinai
$10,238,775
Attributed
$15,541,217
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,541,217 · 4
By mechanism
U01$7,362,213 · 1
R01$7,322,071 · 2
K23$856,933 · 1
Top collaborators
- Yuen Ping Toco Chui4 shared
- Abdullah Kutlar3 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Yuen Ping Toco Chui$4,972,261
- Joan Christine Han$180,625
- Jeffrey Downey$167,940
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaPainHemolysisMorbidity - Disease RateEventCessation Of LifeMortalityBiological MarkersBiologicalAffectEnrollmentHemoglobinSymptomsLungFutureErythrocytesCaringPhenotypeFundingMonitorOrganBlood VesselsResponseDiagnosis
Grant awards (19)
"REAL Answers" (Registry Expansion Analyses to Learn)$2,405,068
U01 · FY2025 · HL · contact PI
SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye$796,719
R01 · FY2025 · HL · contact PI
"REAL Answers" (Registry Expansion Analyses to Learn)$2,389,467
U01 · FY2024 · HL · contact PI
SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye$793,654
R01 · FY2024 · HL · contact PI
"REAL Answers" (Registry Expansion Analyses to Learn)$2,567,678
U01 · FY2023 · HL · contact PI
SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye$814,921
R01 · FY2023 · HL · contact PI
SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye$837,378
R01 · FY2022 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$768,926
R01 · FY2022 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$785,467
R01 · FY2021 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$13,428
R01 · FY2021 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$803,476
R01 · FY2020 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$72,222
R01 · FY2020 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$818,950
R01 · FY2019 · HL · contact PI
IMPROVE 2: Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events$816,930
R01 · FY2018 · HL · contact PI
Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE)$192,143
K23 · FY2017 · HL · contact PI
Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE)$192,201
K23 · FY2016 · HL · contact PI
Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE)$157,578
K23 · FY2015 · HL · contact PI
Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE)$157,578
K23 · FY2014 · HL · contact PI
Inhaled Mometasone to Promote Reduction in Vaso-occlusive Events (IMPROVE)$157,433
K23 · FY2013 · HL · contact PI